-+ 0.00%
-+ 0.00%
-+ 0.00%

Ernexa says ERNA-101 preclinical data win flash talk slot at Nature-MD Anderson cancer meeting

PUBT·10/06/2026 12:57:04
Ernexa says ERNA-101 preclinical data win flash talk slot at Nature-MD Anderson cancer meeting
  • Ernexa Therapeutics disclosed new preclinical results for ERNA-101, selected for a Flash Talk at a Nature Conferences meeting.
  • Data will be presented Tuesday, Oct. 6, 2026, at MD Anderson’s Next-Generation Cancer Therapeutics meeting in Houston.
  • In ovarian cancer models, ERNA-101 drove immune-cell recruitment, shifted tumors toward immune activity, improved tumor control, survival.
  • Combination with PD-1 blockade strengthened responses, delivering complete tumor control, durable responses in most treated animals.
  • Biodistribution work indicated tumor-site localization, with no detectable signal in sampled fluids or other organs evaluated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060855PRIMZONEFULLFEED9839868) on October 06, 2026, and is solely responsible for the information contained therein.